Claims for Patent: 9,387,191
✉ Email this page to a colleague
Summary for Patent: 9,387,191
Title: | Ferric citrate dosage forms |
Abstract: | Disclosed herein are ferric citrate-containing tablets. In various embodiments, the tablets include ferric citrate formulations that meet certain dissolution, tableting and disintegration standards. In various aspects, the tablet formulations can include ferric citrate as the active ingredient and a binder. The formulations also can include a lubricant and/or a disintegrant (which, in some embodiments, can be the same as the binder). |
Inventor(s): | Le; Henry Trong (Englewood Cliffs, NJ) |
Assignee: | Keryx Biopharmaceuticals, Inc. (New York, NY) |
Application Number: | 13/255,326 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 9,387,191 |
Patent Claims: |
1. A ferric citrate tablet comprising: (a) a core comprising approximately 90% to approximately 92% by weight of ferric citrate, approximately 4.5% to approximately 30% by
weight of pregelatinized starch, and approximately 0.5% to approximately 3% by weight of a lubricant; and (b) a coating, wherein the tablet has a friability equal or less than 1% w/w, and wherein at least 80% of the ferric citrate in the tablet is
dissolved in less than or equal to 60 minutes as measured by test method USP <711>, and the moisture content of the tablet is less than 10% by loss on drying (LOD).
2. The tablet of claim 1, wherein the lubricant is magnesium stearate. 3. The tablet of claim 1, wherein the lubricant is calcium stearate. 4. The tablet of claim 1, wherein the tablet comprises approximately 1000 mg of ferric citrate. 5. The tablet of claim 1, wherein the tablet has a disintegration time equal to or less than 30 minutes. 6. A ferric citrate tablet comprising: (a) a core comprising approximately 90% to approximately 92% by weight of ferric citrate, approximately 4.5% to approximately 30% by weight of pregelatinized starch, and approximately 0.5% to approximately 3% by weight of a lubricant; and (b) a coating, wherein the tablet has a friability equal or less than 1% w/w, and wherein at least 80% of the ferric citrate is dissolved in less than or equal to 60 minutes as measured by test method USP <711>, and the moisture content of the tablet is between 5% to 10% by LOD. 7. The tablet of claim 6, wherein the lubricant is magnesium stearate. 8. The tablet of claim 6, wherein the lubricant is calcium stearate. 9. The tablet of claim 6, wherein the tablet comprises approximately 1000 mg of ferric citrate. 10. The tablet of claim 6, wherein the tablet has a disintegration time equal to or less than 30 minutes. 11. A ferric citrate tablet comprising: (a) a core comprising approximately 90% to approximately 92% by weight of ferric citrate, approximately 1.5% to approximately 15% by weight of pregelatinized starch, and approximately 0.5% to approximately 3% by weight of a lubricant; and (b) a coating, wherein the tablet has a friability equal or less than 1%, and wherein at least 80% of the ferric citrate in the tablet is dissolved in less than or equal to 60 minutes as measured by test method USP <711>, and the moisture content of the tablet is between 5% to 10% by LOD. 12. The tablet of claim 11, wherein the lubricant is magnesium stearate. 13. The tablet of claim 11, wherein the lubricant is calcium stearate. 14. The tablet of claim 11, wherein the tablet comprises approximately 1000 mg of ferric citrate. 15. The tablet of claim 11, wherein the tablet has a disintegration time equal to or less than 30 minutes. 16. A ferric citrate tablet containing approximately 210 mg of ferric iron, wherein the tablet comprises: (a) a core comprising approximately 87.6% by weight of ferric citrate, approximately 10% by weight of pregelatinized starch, and approximately 2.4% by weight of calcium stearate; and (b) a coating, wherein the tablet has a friability equal or less than 1% w/w and a disintegration time less than 15 minutes, and wherein at least 80% of the ferric citrate in the tablet is dissolved in less than or equal to 60 minutes as measured by test method USP <711>, and the moisture content of the tablet is 8.84% (LOD). |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.